The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to cover the costly drug.
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
The findings shed light on the long-term effects of Wegovy and add to growing evidence of the weekly injection's broad health benefits. That could boost Novo Nordisk's case for insurers and governments to cover the costly but effective drug. Participants were not required to track diet and exercise because it was not an obesity study. Patients in the trial lost around 10% of their total body weight on average after 65 weeks on Wegovy, according to the first analysis published in the journal Nature.
For example, the reduced risk of serious cardiovascular events for those on Wegovy, compared with placebo, was similar among people who lost 5% or more of their body weight, those who lost less than that or even those who gained weight.
Biotechnology Biotech And Pharmaceuticals Pharmaceuticals Health Care Industry Novo Nordisk A/S Science Social Issues Novo Nordisk A/S Eli Lilly And Co Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than doubleSales of popular weight loss drug Wegovy more than doubled to 9.38 billion kroner.
Read more »
Novo Nordisk announces $6B investment in Ozempic, Wegovy amid shortagesNovo Nordisk's Negelle Morris spoke exclusively with ABC News.
Read more »
Wegovy maker Novo Nordisk down 4%, heads for worst day since OctoberAnalysts pored over the details in its first-quarter results and monitored a potential rival weight loss treatment.
Read more »
Wegovy maker Novo Nordisk down 4%, heads for worst day since OctoberAnalysts pored over the details in its first-quarter results and monitored a potential rival weight loss treatment.
Read more »
Novo Nordisk To Slash Prices On Buzzy Drugs Ozempic and WegovyScience and Technology News and Videos
Read more »
US Senate committee investigates pricing of Novo's Ozempic and WegovyUS Senate committee investigates pricing of Novo's Ozempic and Wegovy
Read more »